The Bloodline

Shieldbearer Studios · 2023 · $19.99 · Action · deal grade A

Measured on 2026-10-04 19:56 UTC. The whole catalog is re-measured daily; a game that just launched can move fast between passes.

Estimated net residual revenue: $3.4k to $5.0k per month
Opportunity: $5.5k per month at x1.30 dormancy
Estimated lifetime owners: 152.0k
83% positive across 3989 reviews · 33.7 reviews/month

Why it's flagged

Developer active, last post 0 months ago
Store page localized in only 1 language(s)
Last discounted 0 months ago, 8 sales in the last 12 months
Proven demand elasticity: x1.2 review velocity during past deep sales

Analyst notes (AI-assisted)

Note written 2026-09-03; the live figures above take precedence over any numbers in it.

The Bloodline is a solo-dev early-access fantasy sandbox that blends Elder Scrolls-style freeform RPG mechanics with Mount & Blade settlement building, skill-based combat, and absurdist physics.

This is a quiet gem with solid four-figure monthly residuals and a devoted, engaged community despite minimal marketing footprint. The developer is actively shipping regular updates to a playerbase that skews hardcore (median 29 hours, 45% still active). For a publisher or studio seeking a niche catalog title with proven longevity and a foundation ready for localization and console porting, this represents low-risk, high-engagement upside at a modest valuation. Most realistic play: acquisition.

Risk: Stability issues recurring in player reports (transition crashes, input-handling bugs, startup failures) may suppress new-player conversion and retention if not addressed before any major push.
Risk: Single-developer bottleneck and early-access status mean scaling production support, QA, and content velocity will require external investment.
Risk: Language support is English-only despite reviews coming from German, Russian, Japanese, Korean, and Simplified Chinese speakers; localization and regional marketing remain untapped.

This case as Markdown · Estimates carry ±30-50% error per title.